Is Rhythm Pharmaceuticals Poised for a Breakthrough in Hypothalamic Obesity

Related Articles

Is Ionis Pharmaceuticals Poised for a Breakthrough with Tryngolza

7 months ago

What Does the FDA's PDUFA Extension Signal for Rhythm Pharmaceuticals

7 months ago

Is TeraDrill (TDRL) Poised for a Breakthrough in Mining Automation

4 months ago

Is EcoSolutions Waste Poised for a Biofuel Breakthrough

7 months ago

Category

You may also like

Stock News•2 weeks ago

Can Novo's Rare Disease Pipeline Add a New Growth Pillar Beyond GLP-1?

Novo Nordisk's rare disease pipeline advanced after Frehemgo and Sogroya received positive CHMP opinions for EU approval, potentially adding growth beyond GLP-1.

GLP

Share

Stock News•2 months ago

Rhythm Pharma's obesity drug shows promise for brain tumor-related weight condition

Rhythm Pharmaceuticals' experimental weekly injectable reduced body weight in patients with a rare obesity form caused by brain damage, per preliminary mid-stage data released Tuesday.

RYTM

Share

Stock News•3 months ago

MBX Biosciences: Weekly PTH, Monthly Obesity, Multi-Year Upside (Initiating Buy)

MBX Biosciences initiated with a speculative buy, driven by Canvuparatide's de-risked Phase 2 profile and differentiated dosing convenience. Phase 3 must address PK variability and long-term calcium c...

MBX

Share